2 research outputs found
ΠΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΎΠ±Π΅Π·Π±ΠΎΠ»ΠΈΠ²Π°Π½ΠΈΡ ΠΏΡΠΈ ΡΠΎΡΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
The authors consider the possibilities of pain management during photodynamic therapy (PDT) of visible tumors based on the observation of 102 patients. Of the total number of patients, 62 had verified basal cell skin cancer, 10 people - squamous cell skin cancer, another 10 - oral and oropharynx mucosa cancer, 8 - oral leukoplakia and dysplasia, in 6 - lower lip cancer, in 4 - breast cancer, in 2 - other localizations of neoplasms. In 15 patients, nonsteroidal anti-inflammatory drugs (NSAID) were used as pain management, in 69 - a combination of NSAID with tramadol, in 14 - nerve block anesthesia, in 4 - PDT was performed under general anesthesia. The intensity of pain syndrome during laser irradiation of the tumor was assessed on the verbal rating scale (VRS). The absence of pain was recorded in 9% of cases. Mild pain was noted by 58% of patients, moderate pain - 20%, severe pain - 10%, very severe pain was noted by 3% of patients.The degree of expression of pain syndrome during PDT depends on the incidence of a lesion, histological form of tumor, and method of anesthesia. NSAID alone, or in combination with an opioid analgesic, allows effective control of pain syndrome in PDT of basal cell skin cancer in 89%, in PDT of squamous cell skin cancer in 66% of observations. Nerve block anesthesia allows stoping pain syndrome during PDT of oropharyngeal tumors.ΠΠ²ΡΠΎΡΡ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΎΠ±Π΅Π·Π±ΠΎΠ»ΠΈΠ²Π°Π½ΠΈΡ ΠΏΡΠΈ ΡΠΎΡΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (Π€ΠΠ’) ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ Π²ΠΈΠ·ΡΠ°Π»ΡΠ½ΡΡ
Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ Π°Π½Π°Π»ΠΈΠ·Π° Π΄Π°Π½Π½ΡΡ
102 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². Π‘ΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², Π²ΠΊΠ»ΡΡΠ΅Π½Π½ΡΡ
Π² Π²ΡΠ±ΠΎΡΠΊΡ, Ρ 62 Π²Π΅ΡΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½ Π±Π°Π·Π°Π»ΡΠ½ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ ΡΠ°ΠΊ ΠΊΠΎΠΆΠΈ, Ρ 10 - ΠΏΠ»ΠΎΡΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ ΡΠ°ΠΊ ΠΊΠΎΠΆΠΈ, Ρ 10 - ΡΠ°ΠΊ ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΠΏΠΎΠ»ΠΎΡΡΠΈ ΡΡΠ° ΠΈ ΡΠΎΡΠΎΠ³Π»ΠΎΡΠΊΠΈ, Ρ 8 - Π»Π΅ΠΉΠΊΠΎΠΏΠ»Π°ΠΊΠΈΡ ΠΈ Π΄ΠΈΡΠΏΠ»Π°Π·ΠΈΡ ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΠΏΠΎΠ»ΠΎΡΡΠΈ ΡΡΠ°, Ρ 6 - ΡΠ°ΠΊ Π½ΠΈΠΆΠ½Π΅ΠΉ Π³ΡΠ±Ρ, Ρ 4 - ΡΠ°ΠΊ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Ρ 2 - Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΈΠ½ΡΡ
Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠΉ.Π£ 15 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π΄Π»Ρ ΠΎΠ±Π΅Π·Π±ΠΎΠ»ΠΈΠ²Π°Π½ΠΈΡ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈ Π½Π΅ΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ (ΠΠΠΠ‘), Ρ 69 - ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ ΠΠΠΠ‘ ΡΠΎ ΡΠ»Π°Π±ΡΠΌΠΈ ΠΎΠΏΠΈΠΎΠΈΠ΄Π°ΠΌΠΈ (ΡΡΠ°ΠΌΠ°Π΄ΠΎΠ»ΠΎΠΌ), Ρ 14 - ΠΏΡΠΎΠ²ΠΎΠ΄Π½ΠΈΠΊΠΎΠ²ΡΡ Π°Π½Π΅ΡΡΠ΅Π·ΠΈΡ, Ρ 4 Π€ΠΠ’ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΏΠΎΠ΄ ΠΎΠ±ΡΠΈΠΌ ΠΎΠ±Π΅Π·Π±ΠΎΠ»ΠΈΠ²Π°Π½ΠΈΠ΅ΠΌ. ΠΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΡΡΡ Π±ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»Π°ΡΡ Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ Π»Π°Π·Π΅ΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±Π»ΡΡΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΏΠΎ ΡΠΊΠ°Π»Π΅ Π²Π΅ΡΠ±Π°Π»ΡΠ½ΡΡ
ΠΎΡΠ΅Π½ΠΎΠΊ (Π¨ΠΠ). ΠΡΡΡΡΡΡΠ²ΠΈΠ΅ Π±ΠΎΠ»Π΅Π²ΡΡ
ΠΎΡΡΡΠ΅Π½ΠΈΠΉ Π·Π°ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½ΠΎ Π² 9% Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ. Π‘Π»Π°Π±ΡΡ Π±ΠΎΠ»Ρ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΈ Π² 58% Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ, ΡΠΌΠ΅ΡΠ΅Π½Π½ΡΡ Π±ΠΎΠ»Ρ β Π² 20%, ΡΠΈΠ»ΡΠ½ΡΡ Π±ΠΎΠ»Ρ - Π² 10%, ΠΎΡΠ΅Π½Ρ ΡΠΈΠ»ΡΠ½ΡΡ Π±ΠΎΠ»Ρ - Π² 3% Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ.Π‘ΡΠ΅ΠΏΠ΅Π½Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΠΈ Π±ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΏΡΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠΈ Π€ΠΠ’ Π·Π°Π²ΠΈΡΠΈΡ ΠΎΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΠΈ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ, Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΎΡΠΌΡ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ ΡΠΏΠΎΡΠΎΠ±Π° ΠΎΠ±Π΅Π·Π±ΠΎΠ»ΠΈΠ²Π°Π½ΠΈΡ. ΠΠΠΠ‘ Π² ΡΠ°ΠΌΠΎΡΡΠΎΡΡΠ΅Π»ΡΠ½ΠΎΠΌ Π²Π°ΡΠΈΠ°Π½ΡΠ΅ ΠΈΠ»ΠΈ Π² ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Ρ ΠΎΠΏΠΈΠΎΠΈΠ΄Π½ΡΠΌ Π°Π½Π°Π»ΡΠ³Π΅ΡΠΈΠΊΠΎΠΌ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΠΎΠ²Π°ΡΡ Π±ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΠΈΠ½Π΄ΡΠΎΠΌ ΠΏΡΠΈ Π€ΠΠ’ Π±Π°Π·Π°Π»ΡΠ½ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΊΠΎΠΆΠΈ Π² 89%, ΠΏΠ»ΠΎΡΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΊΠΎΠΆΠΈ β Π² 66% Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠΉ. ΠΡΠΎΠ²ΠΎΠ΄Π½ΠΈΠΊΠΎΠ²Π°Ρ Π°Π½Π΅ΡΡΠ΅Π·ΠΈΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΊΡΠΏΠΈΡΠΎΠ²Π°ΡΡ Π±ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΠΈΠ½Π΄ΡΠΎΠΌ ΠΏΡΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠΈ Π€ΠΠ’ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΎΡΠΎΡΠ°ΡΠΈΠ½Π³Π΅Π°Π»ΡΠ½ΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ
Possibilities of pain management during photodynamic therapy
The authors consider the possibilities of pain management during photodynamic therapy (PDT) of visible tumors based on the observation of 102 patients. Of the total number of patients, 62 had verified basal cell skin cancer, 10 people - squamous cell skin cancer, another 10 - oral and oropharynx mucosa cancer, 8 - oral leukoplakia and dysplasia, in 6 - lower lip cancer, in 4 - breast cancer, in 2 - other localizations of neoplasms. In 15 patients, nonsteroidal anti-inflammatory drugs (NSAID) were used as pain management, in 69 - a combination of NSAID with tramadol, in 14 - nerve block anesthesia, in 4 - PDT was performed under general anesthesia. The intensity of pain syndrome during laser irradiation of the tumor was assessed on the verbal rating scale (VRS). The absence of pain was recorded in 9% of cases. Mild pain was noted by 58% of patients, moderate pain - 20%, severe pain - 10%, very severe pain was noted by 3% of patients.The degree of expression of pain syndrome during PDT depends on the incidence of a lesion, histological form of tumor, and method of anesthesia. NSAID alone, or in combination with an opioid analgesic, allows effective control of pain syndrome in PDT of basal cell skin cancer in 89%, in PDT of squamous cell skin cancer in 66% of observations. Nerve block anesthesia allows stoping pain syndrome during PDT of oropharyngeal tumors